TuHURA Biosciences — Third Quarter 2026 Earnings Summary

Financial Performance:

• Cash and cash equivalents totaled $1.9 million as of September 30, 2026.
• The Company received $9.2 million in gross proceeds from the Parkview credit facility as of September 30, 2026.
• Research and development expenses were $3.7 million for the three months ended September 30, 2026, a decrease of $1.3 million (26%) compared to $5.0 million in the same period in 2025, driven by lower manufacturing costs.
• General and administrative expenses were $2.0 million for the three months ended September 30, 2026, an increase of $0.4 million (25%) compared to $1.6 million in the same period in 2025, primarily due to higher non-cash stock compensation and public company costs.
• Net cash outflows from operating activities were $18.1 million for the nine months ended September 30, 2026, compared to $22.1 million in the same period in 2025.
• Net cash flows from financing activities were $16.5 million for the nine months ended September 30, 2026, compared to $13.4 million in the same period in 2025.
• Total common shares outstanding were approximately 65.8 million at September 30, 2026.

Guidance and Future Outlook:

• IFx-2.0: Expect to receive orphan drug designation in Merkel Cell Carcinoma (MCC) in the second half of 2026; anticipate preliminary results from the front-line study in the first half of 2027; expect to complete enrollment in the Phase 3 registrational study in the second half of 2027.
• TBS-2025: Expect to initiate a Phase 1b/2 trial in mutNPM1 relapsed/refractory AML in the second half of 2026; anticipate receiving orphan drug designation in AML and preliminary safety/response data in the first half of 2027.
• MDSC Inhibitors: Plan to present data at the ASH Annual Meeting and initiate ADC in vivo proof-of-concept studies in the second half of 2026.
• Management indicated that the $50 million credit facility from the largest shareholder allows for non-dilutive funding to reach value-creating milestones.

Business Segments and Product Lines:

• IFx-2.0 (Innate Immune Agonist): Preliminary data from an open-label study combining IFx-2.0 with Keytruda® in first-line treatment of deep-seated metastatic Merkel Cell Carcinoma showed durable, major objective anti-tumor responses in the first three patients, with all responses ongoing for more than six months.
• TBS-2025 (VISTA Inhibitor): Received FDA "Study May Proceed" notice and IND clearance for a Phase 1b study in patients with relapsed/refractory mutNPM1 AML who failed Menin inhibitor therapy; if dose-optimization shows encouraging response rates, the Company will explore expansion for accelerated approval.
• Delta Opioid Receptor (DOR) Technology: Announced three poster presentations at the 68th ASH Annual Meeting highlighting the role of DOR in controlling immunosuppressive capabilities of myeloid-derived suppressor cells (MDSCs) across MDSCs, T regs, and M2 macrophages.
• Patent Portfolio: Received a new U.S. patent broadening coverage for TBS-2025 to include bispecific/multi-specific antibodies and treatment areas beyond cancer (e.g., autoimmune disease, infection) with a term extending to 2042; received a key U.S. patent for DOR Antibody Drug Conjugate (ADC) technology covering uses beyond ADCs, including CAR-T, Tregs, and TIL cell therapies, with a term extending to 2043.

Market and Competitive Landscape:

• TuHURA is a Phase 3 immuno-oncology company focused on overcoming primary and acquired resistance to cancer immunotherapy.
• The mutNPM1 r/r AML subgroup represents approximately 35% of patients with AML.
• The Company's DOR technology targets the central role of DOR in controlling proliferation, recruitment, and immunosuppressive capabilities of MDSCs, which are the body's main cell type for suppressing immune responses leading to acquired resistance.

Risks and Challenges:

• Forward-looking statements note risks that funds under the credit facility may be insufficient to fund operations and development programs as anticipated.
• Risks include those associated with the ongoing Phase 3 trial for IFx-2.0, the development of TBS-2025 and DOR technologies, and the planned Phase 1b trial for TBS-2025.
• Potential challenges include patient enrollment, trial design, data outcomes, regulatory interactions, and uncertainty regarding the timing and likelihood of milestones and regulatory approvals.
• Actual results may differ materially from forward-looking statements due to these factors and others detailed in the Company's Form 10-K.

Management Commentary and Tone:

• Dr. James Bianco, President and CEO, stated the Company is making "significant progress across each of our programs" and is "well positioned to deliver on several transformational potential milestones."
• Management highlighted the strategic value of the non-dilutive $50 million credit facility in benefiting shareholders while driving toward value-creating events.
• The tone emphasized strong operational focus, noting the ability to proceed on all fronts while maintaining shareholder value.

Other Key Points:

• The Parkview loan facility contributed $5.6 million in non-dilutive financing during the quarter ended September 30, 2026.
• The Company will have a strong presence at the upcoming American Society of Hematology (ASH) Annual Meeting in December with three poster presentations.
• Manufacturing costs are expected to resume in the next quarter with the start of the TBS-2025 clinical trial material manufacturing campaign.
• The Company maintains a corporate update website and social media presence (Facebook, X, LinkedIn) for investor information.